Taj Pharma supplies DEFRATAJ Deferasirox into regulated and emerging markets across four major regions: LATAM, Africa, Asia and CIS. Each region has distinct regulatory, commercial and clinical characteristics - our commercial team adapts supply and registration plans accordingly.
Regional Overview #
Africa
High burden of sickle-cell disease and beta-thalassemia; WHO-PQ aligned national authorities (NAFDAC, PPB, TFDA/TMDA, MCAZ, SAHPRA). Strong public-sector tender channels. See Africa lander.
LATAM
Sophisticated regulators (ANVISA, COFEPRIS, INVIMA, DIGEMID, ANMAT) - typically require more detailed BE and clinical data. Strong institutional purchasing through social security systems.
Asia
Diverse regulatory landscape from ACTD-format authorities (Philippines, Vietnam, Malaysia, Indonesia, Thailand) through Central Drugs Standard Control Organization (India) to MOH Saudi Arabia / UAE and other GCC markets.
CIS
Russian Federation and Eurasian Economic Union (EAEU) pathways - GMP inspection plus dossier assessment. Individual CIS markets accept nationally registered products.
Market-Entry Approach #
- Opportunity assessment - market size, pricing reference, registration pathway, key customer segments
- Partner appointment - exclusive / semi-exclusive distributor aligned to channel structure
- Dossier compilation & submission - country-specific Module 1 + Taj Pharma Modules 2-5
- Approval & launch - launch pack preparation, pharmacovigilance agreement, supply plan
- Lifecycle management - variations, renewals, supply scaling
Typical Registration Timeline #
| Region | Typical Elapsed Time |
|---|---|
| African WHO-PQ aligned markets | 6-18 months |
| LATAM (sophisticated regulators) | 12-30 months |
| ACTD markets (SE Asia) | 9-24 months |
| GCC | 9-18 months |
| CIS | 12-24 months (incl. GMP inspection) |
Key Success Factors #
- Early engagement with our regulatory team to select the right pathway
- Partner with in-country regulatory capability
- Realistic pricing strategy aligned to reference markets and tender dynamics
- Consistent pharmacovigilance and quality interface